Saturday, January 24, 2015

Don't do it again in NSCL Cancers

Clinically Negative phase III trials with Antiangiogenics (and their targets) in NSCL cancers:

1.Thalidomid  -----an Antiangiogenic drug
2.Cediranib---------VEGFR TKI
3.Vandetanib--------Multikinase TKI
4.Sorafenib---------Multikinase TKI
5.Sunitinib----------Multikinase TKI
6.Aflibercept------------VEGF/PIGF

(from C.Langer notes)
Post a Comment